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Abstract
The only curative treatment in biliary tract cancer is surgical 
treatment. Therefore, the suitability of curative resection 
should be investigated in the ﬁ  rst place. In the presence of 
metastasis to the liver, lung, peritoneum, or distant lymph 
nodes, curative resection is not suitable. No deﬁ  nite consensus 
has been reached on local extension factors and curability. 
Measures of hepatic functional reserve in the jaundiced liver 
include future liver remnant volume and the indocyanine 
green (ICG) clearance test. Preoperative portal vein emboli-
zation may be considered in patients in whom right hepatec-
tomy or more, or hepatectomy with a resection rate exceeding 
50%–60% is planned. Postoperative complications and 
surgery-related mortality may be reduced with the use of 
portal vein embolization. Although hepatectomy and/or pan-
creaticoduodenectomy are preferable for the curative resec-
tion of bile duct cancer, extrahepatic bile duct resection alone 
is also considered in patients for whom it is judged that cura-
tive resection would be achieved after a strict diagnosis of its 
local extension. Also, combined caudate lobe resection is rec-
ommended for hilar cholangiocarcinoma. Because the prog-
nosis of patients treated with combined portal vein resection 
is signiﬁ  cantly better than that of unresected patients, com-
bined portal vein resection may be carried out. Prognostic 
factors after resection for bile duct cancer include positive 
surgical margins, especially in the ductal stump; lymph node 
metastasis; perineural invasion; and combined vascular resec-
tion due to portal vein and/or hepatic artery invasion. For 
patients with suspected gallbladder cancer, laparoscopic cho-
lecystectomy is not recommended, and open cholecystectomy 
should be performed as a rule. When gallbladder cancer 
invading the subserosal layer or deeper has been detected 
after simple cholecystectomy, additional resection should be 
considered. Prognostic factors after resection for gallbladder 
cancer include the depth of mural invasion; lymph node 
metastasis; extramural extension, especially into the hepato-
duodenal ligament; perineural invasion; and the degree of 
curability. Pancreaticoduodenectomy is indicated for ampul-
lary carcinoma, and limited operation is also indicated for 
carcinoma in adenoma. The prognostic factors after resection 
for ampullary carcinoma include lymph node metastasis, pan-
creatic invasion, and perineural invasion.
Key words Biliary tract neoplasms · Bile duct neoplasms · Gall-
bladder neoplasms · Ampulla of Vater · Surgery · Guidelines
Introduction
At present, there are no opinions against the suitability 
of surgical resection as the only curative treatment for 
biliary tract cancer. Therefore, the ﬁ  rst thing to do is to 
consider the suitability of surgical resection in each 
patient in whom a diagnosis of biliary tract cancer has 
been made. Shown in Fig. 1 are postoperative long-term 
results reported in the Biliary Tract Cancer Statistics 
Registry in Japan 1988–1997
1 for resected patients.
The classiﬁ  cation of biliary tract cancers is made 
according to the Japanese Society of Biliary Surgery 
Classiﬁ  cation of biliary tract carcinoma.
2 On the basis of 
the site of occurrence, biliary tract carcinomas are clas-
siﬁ  ed as intrahepatic and extrahepatic bile duct cancers, 
ampullary cancer, and gallbladder cancer. For the 
classiﬁ  cation of hilar cholangiocarcinoma, not only the 
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Classiﬁ  cation of biliary tract carcinoma (Fig. 2)
2 but also 
the Bismuth classiﬁ  cation (Fig. 3)
3 is often employed. 
These are topical classiﬁ  cations of bile duct carcinoma 
based on longitudinal tumor spread.
Due to the paucity of cases of surgical treatment of 
biliary carcinoma and the diversity of surgical proce-
dures, little high-level evidence has been accumulated 
in this ﬁ  eld. Especially in advanced biliary carcinoma, 
a great difference is observed in surgical indications 
among institutions. Disparities in postoperative results 
are also seen.
The surgical magnitude is great in extended opera-
tions for advanced biliary carcinoma, which leads to the 
development of complications. Thus, these operations 
should be performed with care at high-volume centers 
with sufﬁ  cient expertise in biliary tract cancer 
operations.
We expect that the data to be accumulated in future 
will help the present guidelines to evolve into more 
deﬁ  nitive revised guidelines. Here, we pose clinical 
Fig. 1.  Survival of patients with resection of gallbladder 
cancer, bile duct cancer, and cancer of the papilla of Vater. 
Percentages show 5-year survival rates.
1 GB, Cancer of the 
gallbladder, BD, cancer of the bile duct; PV, cancer of the 
papilla of Vater. Postoperative survival after resection of 
biliary cancer
Fig. 2.  Anatomical nomenclature of the 
biliary tract (Japanese Society of Biliary 
Surgery. Classiﬁ  cation of biliary tract car-
cinoma. Second English edition. Tokyo: 
Kanehara; 2004),
2 with permission
Fig. 3.  Modiﬁ  ed Bismuth-Corlette clas-
siﬁ  cation (from Bismuth H, Nakache R, 
Diamond T. Management strategies in 
resection for hilar cholangiocar-
cinoma. Ann Surg 1992;215:31–8.),
3 with 
permissionS. Kondo et al.: Guidelines for the surgical treatment of biliary cancer  43
questions (CQs) regarding surgical treatment for biliary 
carcinoma. In the responses to the CQs, recommenda-
tions for treatment are noted (grades of these recom-
mendations are deﬁ  ned in Table 1
4). Also, levels of 
evidence are given (in parentheses) for ﬁ  ndings in refer-
ence citations (see deﬁ  nitions of levels in Table 2
4).
Concerning factors involved in the local extension 
of hilar cholangiocarcinoma and gallbladder cancer, 
general evaluation of their extension to the bile duct, 
portal vein, and hepatic artery should be made. Jarnagin 
et al.
5 (level IV) deﬁ  ned unresectable factors involved 
in the local extension of hilar cholangiocarcinoma as 
follows:
1.  Tumor extension to secondary biliary radicles 
bilaterally
2. Encasement or occlusion of the main portal vein 
proximal to its bifurcation
3.  Atrophy of one hepatic lobe with contralateral portal 
vein branch encasement or occlusion
4.  Atrophy of one hepatic lobe with contralateral tumor 
extension to secondary biliary radicles
5.  Unilateral tumor extension to secondary biliary rad-
icles with contralateral portal vein branch encase-
ment or occlusion
The deﬁ  nition of unresectable gallbladder cancer is 
made based on almost the same criteria
6  (level IV). 
Concerning hilar cholangiocarcinoma, however, there 
are reports on more aggressive surgical approaches, 
such as combined resection and reconstruction of the 
portal vein and/or hepatic artery
7 (level IV) and left 
trisectionectomy
8 (level IV), but there is no consensus 
at present on local extension factors in unresectable 
cases. Also, for middle/lower bile duct cancer, there are 
reports on combined portal vein resection
9 (level IV) 
and combined hepatic artery resection
10 (level IV), but 
there is no consensus to date on local extension factors 
in unresectable cases.
Weber et al.
6 (level IV) deﬁ  ne cases up to N1 with 
hilar cholangiocarcinoma and gallbladder cancer 
(metastasis to lymh node in the hepatoduodenal liga-
ment) as resectable cases and N2 cases (metastasis to 
peripancreatic lymph node) as unresectable cases. 
However, in Japan, aggressive surgical resection is also 
being performed for cases of N2 hilar cholangiocarci-
noma and gallbladder cancer
11,12 (level IV). At least as 
far as gallbladder cancer is concerned, metastasis to the 
paraaortic lymph node is considered as distant metasta-
sis, similar to liver and peritoneal metastases
11,13 (level 
IV). There is a report that, for bile duct cancer, macro-
Included in these factors are metastases to the liver, 
lung, peritoneum, and distant lymph node. There is 
no consensus for local extension.
As in other malignant diseases, judgment concerning 
the suitability of surgical resection for biliary cancer 
should be made on the basis of the evaluation of factors 
such as general condition, local extension of tumor, and 
metastasis (lymph node, liver, peritoneum, lung, etc)
5,6 
(level IV). In deﬁ  ning “unresectability,” noncurative 
resection is regarded as “unresectable” even if local 
resection is technically possible.
Decisions on the tolerance of the patient’s general 
condition to surgical operation differ depending upon 
the surgical extent of the operative procedure. In biliary 
tract cancer, major surgery is often needed, including 
hepatectomy and/or pancreaticoduodenectomy. Careful 
preoperative evaluation should be made of the func-
tions of the liver, heart, lung, and kidney, including per-
formance status.
CQ 1  What unresectable factors are there for biliary 
cancer?
Table 1.  Strength of recommendations
4
A, Strongly recommend performing the clinical action
B, Recommend performing the clinical action
C1, The clinical action may be considered although there is a 
lack of high-level scientiﬁ  c evidence for its use. May be 
useful
C2, Clinical action not deﬁ  nitively recommended because of 
insufﬁ  cient scientiﬁ  c evidence. Evidence insufﬁ  cient to 
support or deny usefulness
D, Recommend not performing the clinical action
Table 2.  Levels of evidence
4
Level I Systematic review/meta-analysis
Level II One or more randomized clinical trials
Level III Nonrandomized controlled trials
Level IV Analytic epidemiology (cohort studies and case-control studies)
Level V Descriptive study (case reports and case-series studies)
Level VI Opinions of expert panels and individual experts not based on 
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carried out, and also the long-term results were similar 
(level IV).
There are no reports of randomized controlled trials 
(RCTs) on whether preoperative portal vein emboliza-
tion contributes to a decreased incidence of postopera-
tive complications such as liver failure and the 
surgery-related mortality rate, but there is a report of a 
prospective cohort study by Farges et al.
20 According to 
this report, there were no differences in the incidence 
of postoperative complications according to whether or 
not preoperative portal vein embolization was per-
formed in 55 patients with hepatocellular carcinoma 
and metastatic liver cancer for whom right hepatectomy 
was conducted, but in patients with chronic liver dis-
eases, the incidence of postoperative complications was 
signiﬁ  cantly lower in the group for whom preoperative 
portal vein embolization was performed (level III).
There are no prospective controlled trials concerning 
biliary tract cancer, so no sufﬁ  cient scientiﬁ  c evidence 
exists. However, in view of the following observations, 
preoperative portal vein embolization may be con-
sidered in patients with jaundiced liver in whom right 
hepatectomy or more, or hepatectomy with a resection 
rate exceeding 50%–60% is planned: (1) Based on the 
decreased incidence of postoperative complications 
brought about by portal vein embolization in patients 
with chronic liver disease, in whom hepatic functional 
reserve was decreased, suggested in the cohort study by 
Farges et al.
20 concerning hepatocellular carcinoma and 
metastatic liver cancer, similar effects may be expected 
in patients with damaged liver even after the resolution 
of jaundice. (2) According to a report on 53 patients 
with hilar cholangiocarcinoma by Hemming et al.,
21 in 
the group in whom hypertrophy of the future liver 
remnant was caused by obstruction of the portal vein 
branch, due to its embolization or cancers, postopera-
tive mortality (3%) was lower than that (21%) in the 
group without hypertrophy (level IV). (3) In multiple 
studies
7,22–24 reporting the use of portal vein emboliza-
tion as a routine preoperative procedure for patients 
undergoing major hepatectomy, no postoperative in-
hospital death occurred; preoperative portal vein embo-
lization may be considered in patients with a jaundiced 
liver undergoing hepatectomy with a resection rate of 
50%–60% (level IV).
Although there is a report showing that there was no 
occurrence of complications associated with portal vein 
embolization itself,
19 the occurrence of other complica-
tions has been reported, such as dislocation of emboliza-
tion materials outside the planned embolization area, 
pneumothorax, hemorrhage, portal vein thrombosis, 
portal hypertension, and transient liver failure.
25–27 
Therefore, indications should be carefully considered, 
especially in patients with normal liver or those with 
planned left hepatectomy.
CQ 2  Is preoperative portal vein embolization useful 
for patients with biliary tract cancer requiring 
hepatectomy?
Preoperative portal vein embolization may be 
considered in patients in whom right hepatectomy or 
more, or hepatectomy with a resection rate exceeding 
50–60% is planned, especially in patients with 
jaundiced liver. It may contribute to the reduction 
of complications and surgery-related mortality 
(recommendation C1).
Embolization of the right portal vein branch for patients 
with biliary carcinoma in whom right hepatectomy or 
more is planned leads to atrophied right liver and a 
signiﬁ  cant increase in future liver remnant volume in 2 
or 3 weeks
17,18 (level IV). On the other hand, it is known 
that, even in patients without portal vein embolization, 
the liver remnant becomes larger after right hepatec-
tomy, but it is not clear whether the rate of hypertrophy 
is similar to that in patients for whom portal vein embo-
lization has been conducted.
According to Nagino et al.,
19  the postoperative in-
hospital mortality rate was 8.8% in the world’s largest 
case series study of biliary tract cancer, in which hepa-
tectomy was performed after portal vein embolization 
(bile duct cancer, 132 cases; gallbladder cancer, 61 cases; 
total, 193 cases). To be more precise, the postoperative 
in-hospital mortality rate was 4.5% in patients with bile 
duct cancer for whom hepatectomy was conducted after 
portal vein embolization. This was signiﬁ  cantly lower 
than the mortality rate in patients with gallbladder car-
cinoma (18%), and similar to that (3.7%) in 136 patients 
with bile duct cancer in whom the liver resection rate 
was 50% or less and no portal vein embolization was 
scopically detectable metastasis to the paraaortic lymph 
node is also considered as distant metastasis, similar to 
liver and peritoneal metastases
12 (level IV).
Most studies report that the metastasis of biliary 
carcinoma to the liver and lung, peritoneal metastasis, 
and distant lymph node metastasis (paraaortic and 
extraperitoneal lymph nodes, etc) are unresectable 
factors
6,11,13,14 (level IV). However, there are a few reports 
showing long-term survival,
15 which are rare and excep-
tional cases. Concerning the preoperative diagnosis of 
peritoneal dissemination and liver metastasis, there is a 
report suggesting the efﬁ  cacy of a laparoscopic search
6 
(level IV). However, a preoperative diagnosis of para-
aortic lymph node metastasis is difﬁ  cult to make
16 (level 
IV), so at present the most reliable procedure to address 
this situation is intraoperative biopsy.S. Kondo et al.: Guidelines for the surgical treatment of biliary cancer  45
CQ 3  Are there effective measures of hepatic 
functional reserve in the jaundiced liver?
Measurement of the future liver remnant volume 
by computed tomography (CT) is useful 
(recommendation B). The indocyanine green (ICG) 
clearance test is useful in assessing hepatic functional 
reserve after relief of jaundice not associated with 
cholangitis (recommendation C1).
In patients with biliary tract cancer, the association of 
jaundiced liver is often observed. As described in CQ2, 
in patients undergoing major hepatectomy such as right 
hepatectomy, or more, portal vein embolization may 
need to be considered in order to increase the future 
liver remnant volume. CT volumetry before and after 
portal embolization is useful to assess its effect.
There are reports on the ICG clearance test and the 
galactose tolerance test after relief of jaundice as a 
method of preoperative assessment of hepatic func-
tional reserve. However, in terms of the occurrence of 
postoperative complications, no signiﬁ  cant difference 
has been observed in the efﬁ  cacy of these tests. Con-
cerning the development of postoperative liver failure, 
the result of the ICG clearance test is considered to 
serve as a predictive factor.
For predicting postoperative death and the develop-
ment of liver failure in patients with liver cirrhosis, the 
usefulness of preoperative assessment of hepatic func-
tional reserve according to the ICG retention rate at 
15  min is widely recognized
28  (level IV). Also, more 
appropriate decision-making is made possible by mea-
suring the ratio of the future remnant liver volume to 
the total liver volume
29 (level IV). Furthermore, Nagino 
et al.
30 reported that four factors: glucose tolerance, the 
presence or absence of cholangitis and pancreaticoduo-
denectomy, and the ICG clearance rate were involved 
(level IV). The ICG retention rate at 15 min is generally 
used in the preoperative assessment of hepatic func-
tional reserve, but the number of patients with jaun-
diced livers in the reports on the preoperative assessment 
of hepatic functional reserve is smaller than the numbers 
of those with normal and cirrhotic livers. There is also a 
report that the occurrence of cholangitis prior to resec-
tion had unfavorable impacts on postoperative results 
even in patients with good hepatic functional reserve
31 
(level IV).
It is considered that the best clinical method at present 
includes the measurement of the future liver remnant 
volume with the use of CT in the ﬁ  rst place, and the 
overall assessment of hepatic functional reserve based 
on the ICG retention rate at 15  min after the relief of 
jaundice, and determination of the presence or absence 
of cholangitis. There is a report that reviewed the ICG 
CQ 4 Is extrahepatic bile duct resection alone 
recommended for upper/middle bile duct cancer?
Although hepatectomy and/or 
pancreaticoduodenectomy are preferable for curative 
resection, extrahepatic bile duct resection alone is 
considered in patients for whom it is judged that 
curative resection can be achieved after a strict 
diagnosis of the local extension of the cancer 
(recommendation C2).
Standard operative procedures in the surgical treatment 
of bile duct cancer are bile duct resection plus hepatec-
tomy for hilar/upper bile duct carcinoma and pancreati-
coduodenectomy (PD) for middle/lower bile duct 
cancer. Many bile duct cancers are associated with 
lymph node metastasis and perineural invasion, in addi-
tion to longitudinal and extramural extensions, and 
tumor remnant in the resection stump and lymph node 
metastasis are reported to be important prognostic 
factors after the resection of bile duct cancer
35 (level 
IV). In the common type of bile duct cancer, a negative 
resection stump is difﬁ  cult to secure by means of bile 
duct resection plus local lymph node dissection alone, 
and lymph node dissection itself is also assumed to be 
often insufﬁ  cient. However, if the cancer is a localized 
type without lymph node metastasis and perineural 
invasion, curative resection may be achieved, theoreti-
cally, with the use of extrahepatic bile duct resection 
(BDR) alone.
36
Jang et al.
37  performed BDR for 27 patients with 
upper/middle bile duct cancer and found a 5-year 
survival rate of 28.0% for these patients (7/25). They 
reported that no signiﬁ  cant difference was observed 
between PD/hepatectomy and BDR alone, the survival 
rate of PD in middle/lower bile duct cancer being 
30.1% (31/103) and that of BDR with hepatectomy in 
upper/middle bile duct cancer being 47.8%(11/23). 
According to their report, prognostic factors after BDR 
are the type of cancer and lymph node metastasis. Bile 
duct resection is recommended for T1 lesions with 
histological ﬁ  ndings of the papillary type or well-
clearance test on the basis of bile excretion volume
32 
(level IV). According to this report, this test may be 
helpful in lobar functional assessment, but it is not 
always suitable because drainage is often carried out for 
one lobe. The galactose tolerance test is also helpful in 
assessing hepatic functional reserve in the jaundiced 
liver, but its evidence level is low
33 (level IV). There is 
a possibility that, as cases in this ﬁ  eld accumulate, a test 
enabling lobar functional assessment
34 (level IV), such 
as 
99mTc-galactosyl human serum albumin (GSA) scin-
tigraphy, may become effective.46  S. Kondo et al.: Guidelines for the surgical treatment of biliary cancer
CQ 6  Should combined portal vein resection be per-
formed for patients with portal vein invasion?
Combined portal vein resection may be performed, 
because the prognosis of patients treated with 
combined portal vein resection is signiﬁ  cantly better 
than that of unresected patients (recommendation 
C1).
Ebata et al.
49 reported combined portal vein resection 
in 52 of 160 patients with resected hilar cholangiocarci-
noma. In patients with combined portal vein resection, 
the cancer was more advanced, but no difference was 
observed in mortality rates between patients with and 
without portal vein resection. The 5-year survival rates 
were 9.9% and 36.8%, respectively, being signiﬁ  cantly 
lower in patients with portal vein resection. There was 
no difference in prognosis on the basis of the presence 
or absence of pathological portal vein invasion. By mul-
tivariate analysis, it was found that factors involved in 
prognosis were the degree of differentiation and the 
presence or absence of lymph node metastasis and mac-
roscopic portal vein invasion. According to the authors, 
portal vein resection contributed to long-term survival 
in a small number of patients with advanced cancer 
(level IV).
Miyazaki et al.
50  conducted combined portal vein 
resection in 41 of 161 patients who underwent resection 
of hilar cholangiocarcinoma. The 5-year survival rates 
in patients with curative resection were 25% and 41% 
for those receiving combined portal vein resection and 
those receiving nonvascular resection, respectively. 
Although the prognosis was signiﬁ  cantly poorer in 
patients with combined vascular resection, it was better 
compared with that in unresectable patients. So, these 
authors reported that combined portal vein resection 
was of signiﬁ  cance (level IV). The same group (Suzuki 
et al.
51) also reported on the usefulness and safety of left 
renal vein graft in the reconstruction of the portal vein 
and inferior vena cava (level IV).
Kondo et al.
52 reported no postoperative in-hospital 
deaths in patients receiving combined portal vein resec-
tion, and they noted that it could be carried out safely; 
no difference was found in postoperative morbidity and 
mortality between these patients and patients with non-
combined resection
7 (level IV).
Hemming et al.
53  conducted combined portal vein 
resection in 26 of 60 patients who underwent curative 
resection for hilar cholangiocarcinoma. They found no 
CQ 5 Is combined caudate lobe resection required 
for hilar/upper bile duct carcinoma?
Combined caudate lobe resection is recommended in 
most cases of hilar/upper bile duct carcinoma 
(recommendation C1).
There are no RCTs reporting on the efﬁ  cacy of caudate 
lobe resection for hilar cholangiocarcinoma. Mizumoto 
et al.
39 (level IV) reported that, in 11 of 24 patients with 
resected hilar cholangiocarcinoma, tumor invasion was 
found in the caudate branches or parenchyma, thus 
demonstrating the importance of caudate resection. 
Also, Nimura et al.
40 (level IV) performed combined 
caudate resection in 45 of 55 patients with resected hilar 
cholangiocarcinoma and achieved a 5-year survival rate 
of 40.5% for 43 patients who underwent curative resec-
tion, concluding that caudate resection is the hepatec-
tomy type of choice.
The present situation in Japan is that combined 
caudate resection is being widely performed for hilar 
cholangiocarcinoma
7,8,22–24 (level IV). This resection is 
being performed after consideration of these reports 
and consideration of the anatomical characteristics of 
caudate branches that directly join the hepatic hilar bile 
duct.
41,42 There is a report that, in the absence of cancer 
invasion to the caudate bile duct branch in patients with 
the Bismuth I type of carcinoma, no difference was 
found in prognosis between patients who underwent 
hepatectomy including caudate resection and those in 
whom curative resection was achieved by hepatic hilar 
resection preserving the caudate lobe
36 (level IV).
Concerning reports from other countries, we have 
found an extremely small number of reports that discuss 
the beneﬁ  ts or harms of combined caudate resection for 
hilar cholangiocarcinoma
43 and, in contrast to the efforts 
in Japan, there is only a limited amount of literature 
discussing caudate resection in review articles.
44–46 
However, at the present time, Italian and Korean groups 
have reported improved survival rates with the use of 
combined caudate resection, and they have stressed the 
differentiated adenocarcinoma, especially in patients 
with poor general condition (level IV).
Good indications for BDR include a papillary type 
of lesion limited to the upper/middle bile duct without 
apparent lymph node metastasis, in which the resection 
stump should be conﬁ  rmed to be negative by intra-
operative pathological diagnosis.
38  For a nodular/
invasive type of tumor, hepatectomy or PD is preferred 
as a rule,
7,38 and BDR may be recommended in patients 
who are judged to be intolerant of hepatectomy or 
PD.
necessity of caudate resection, considering the lack of 
established diagnostic methods to judge invasion to the 
caudate bile duct branch
47,48 (level IV).S. Kondo et al.: Guidelines for the surgical treatment of biliary cancer  47
exists between the degree of lymph node metastasis and 
prognosis, and that the important factor in determining 
the prognosis is the presence or absence of lymph node 
metastasis. Furthermore, there is a report indicating that 
the prognosis of patients with lymph node metastasis is 
generally poor, but for those in whom metastasis is 
limited to the regional lymph node, the prognosis is not 
always poor if systematic lymph node dissection is per-
formed
59  (level IV). Also, on the basis of results of 
univariate and multivariate analyses, the presence or 
absence of lymph node metastasis is thought to be an 
important prognostic factor after resection.
There is a report suggesting that perineural invasion 
is also an important mode of extension in bile duct 
cancer and that its presence or absence is a factor 
involved in the prognosis after resection of this cancer
61 
(level IV).
In multivariate analysis that included patients who 
underwent combined vascular resection due to the inva-
sion of the portal vein and/or hepatic artery, vascular 
resection was reported as one of the negative prognostic 
factors
49,62 (level IV).
The curative resectability of middle/lower bile duct 
cancer as well as hilar cholangiocarcinoma has the 
largest impact on prognosis. It is reported that the 
absence of a cancer remnant in the resection stump and 
surgical margin is of utmost importance, but that lymph 
node metastasis is an important prognostic factor as 
well
35,63 (level IV).
There are reports that found a correlation between 
perineural invasion and prognosis
43,61 (level IV), while 
another report failed to ﬁ  nd such a correlation
35 (level 
IV).
Thus, in bile duct cancer, an important factor that has 
a large impact on prognosis is whether the resection 
was curative or not; therefore, a detailed examination 
of the resected sample is of signiﬁ  cance. Patients with 
positive surgical margins or with positive lymph nodes 
have a higher possibility of recurrence. Strict follow-
up and postoperative adjuvant therapy should be 
considered.
CQ 7  What are the prognostic factors after resection 
of bile duct cancer?
Included in these factors are positive surgical 
margins, especially in the ductal stump; lymph node 
metastasis; perineural invasion; and combined 
vascular resection due to portal vein and/or hepatic 
artery invasion.
Kondo et al.
7 summarized reports of multivariate analy-
sis of prognostic factors after resection of hilar cholan-
giocarcinoma after resection. According to their study, 
9 of 11 reports suggested the presence or absence of R0 
(curative resection), as the factor with the greatest 
impact on prognosis. Because the prognosis in cura-
tively resected patients is signiﬁ  cantly better than that 
in patients with noncurative resection and unresectable 
patients, achieving curative resection is of great impor-
tance. Particularly, a large number of studies
43,55–59 have 
suggested the absence of cancer remnant in the resec-
tion stump and surgical margin as an important factor 
that contributes to achieving a good prognosis (level 
IV). However, a cancer remnant in the mucosa of the 
ductal stump has been said by others to have no impact 
on prognosis
60 (level IV).
In patients who have undergone curative resection, 
the presence or absence of lymph node metastasis has 
a large impact on their prognosis
2,56–58 (level IV). There 
is a report
56 (level IV) suggesting that no correlation 
CQ 8 Should open cholecystectomy be performed 
instead of laparoscopic cholecystectomy for patients 
with suspected gallbladder cancer?
For patients with suspected gallbladder cancer, 
laparoscopic cholecystectomy is not recommended, 
and open cholecystectomy should be performed as 
a rule (recommendation C1).
Laparoscopic cholecystectomy (LC) is the ﬁ  rst choice 
for cholecystolithiasis, and there is a tendency to extend 
its indication to patients with suspected gallbladder 
signiﬁ  cant difference between patients with and without 
portal vein resection in the occurrence of complications 
and mortality rates, frequency of positive resection 
stump, and 5-year survival rates (patients with portal 
vein resection, 39%; patients without portal vein resec-
tion, 41%). Multivariate analysis showed that the only 
factor responsible for prognosis was the presence of a 
positive resection stump. According to their report, 
portal vein resection is a safe procedure and may con-
tribute to longer survival (level IV).
Portal vein invasion in hilar cholangiocarcinoma is 
one of the factors that determines resectability and the 
method of resection.
5  Several studies have reported 
cases which became resectable with the use of com-
bined portal vein resection. It is suggested that the 
prognosis of resected patients was better than that of 
unresectable cases. However, many of the patients com-
pared were unresectable not necessarily because of 
portal vein invasion. Therefore, the strength of recom-
mendation for resection was graded as category C1 due 
to the lack of sufﬁ  cient scientiﬁ  c evidence to clarify the 
signiﬁ  cance of combined portal vein resection
49,50,53,54 
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cancer. However, in LC, the dissection plane on the liver 
side is within the subserosal layer. If the lesion has 
extended beyond the muscular layer, a cancer remnant 
may result. If a mucosal carcinoma in the Rokitansky-
Ashoff sinus (RAS) extending beyond the muscular 
layer exists on the liver side, a cancer remnant may also 
result. Even in whole-layer cholecystectomy, in which 
the hepatic parenchyma is exposed, the subserosal layer 
may be exposed if a subserosal cancer has extended 
deep into the layer. The resectable extent with LC is 
rather limited and, at least, LC should not be used for 
a lesion on the liver side.
The methods and procedures for lymph node dissec-
tion and combined resection of the liver for gallbladder 
cancer have not been established as laparoscopic pro-
cedures. Therefore, these steps are not recommended at 
present.
In a study of 123 patients with polypoid lesions, 
carried out by Yeh et al.,
64 only 2 (2.1%) of the 28 neo-
plastic lesions were less than 10 mm in diameter and all 
of the 7 malignant lesions were 15 mm or more. On the 
basis of mutlivariate analysis including these data, it was 
shown that polyps 10 mm or more in diameter are neo-
plastic, and it is probable that polyps of 15 mm or more 
are malignant (level IV). Therefore, polypoid lesions 
with a largest diameter of less than 10 mm may be con-
sidered in indications for LC, but for lesions larger than 
10 mm, careful attention should be paid to the suspected 
gallbladder cancer, especially in the case of lesions on 
the liver side.
When LC is applied for gallbladder cancer, port-site 
recurrence (PSR) and peritoneal recurrence occurring 
as a result of bile leak associated with gallbladder injury 
are serious problems. Wakai et al.
65 reported, in their 
study of LC, that, of 28 patients with gallbladder cancer, 
gallbladder injury occurred in 25%, of whom PSR or 
local recurrence developed in 43%, and the survival rate 
was signiﬁ  cantly lower in patients with gallbladder 
injury (level IV). Ouchi et al.
66 found that gallbladder 
perforation occurred in 20% of patients with gallblad-
der cancer, and that the prognosis was signiﬁ  cantly 
poorer in patients with perforation than in patients 
without perforation. In their report, the recurrence rate 
in patients with and without gallbladder perforation was 
27% and 14%, respectively, being signiﬁ  cantly higher in 
the former group. There are also reports concerning 
cases of intraepithelial carcinoma
67 and mucosal cancer
68 
in which early death occurred due to peritoneal dis-
semination as a result of gallbladder perforation (level 
V).
It is reported that the incidence of PSR after LC 
was 11%–16%,
65,69–71  and the time to onset was 6–10 
months.
69–71 There is a report showing that the prognosis 
of patients with PSR was poor; all the patients had 
associated peritoneal dissemination, and the median 
Table 3.  Depth of mural invasion of gallbladder cancer
a
m Invasion limited to the mucosa
mp Invasion limited to the muscularis propria
ss Invasion limited to the subserosa
se Invasion of the serosal surface
si Invasion beyond the serosa and invasion of other 
organs or structures
a Japanese Society of Biliary Surgery (JSBS). Classiﬁ  cation of biliary 
tract carcinoma, Second English edition 2004.
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CQ 9 Is an additional resection required when 
gallbladder cancer invading the subserosal layer 
or deeper has been detected after simple 
cholecystectomy?
An additional resection should be considered 
(recommendation C1).
With the recent progress in diagnostic imaging, a diag-
nosis of advanced gallbladder cancer can be made prior 
to operation in many patients. But it is reported that the 
frequency of diagnosis of gallbladder cancer being made 
serendipitously by postoperative pathological examina-
tions of gallbladders resected for gallstones is approxi-
mately 1%.
67,75,76 In patients in whom a diagnosis of m 
or mp cancer (see Table 3 for deﬁ  nitions of depth of 
mural invasion of gallbladder cancer) has been made by 
pathological examination of the entire gallbladder, an 
additional resection is not necessary as a rule if the 
survival period was 19 months
71 (level IV). There are 
studies comparing the incidence of PSR with that of 
wound recurrence in patients who underwent open 
cholecystectomy (OC). According to these studies, the 
incidence (LC: OC) was 15%: 6.5%,
72 and 11%: 4%,
73 
respectively (level IV). It is thought that, in addition to 
intraoperative bile leak, such factors as the biological 
properties of the tumor, tumor stage, operative maneu-
vers, and the impact of pneumoperitoneal pressure and 
carbon dioxide on tumor cells and the living body are 
involved in the onset of PSR.
69
LC can now be safely performed for cholecystolithia-
sis because of technical improvements and advances in 
instrumentation. It is speculated that, theoretically, LC 
can be indicated for early gallbladder cancer with intra-
mural invasion up to the muscular layer, but the accu-
rate preoperative diagnosis of the depth of mural 
invasion is difﬁ  cult even with full use of ultrasonogra-
phy, CT, and endoscopic ultrasonography (EUS)
74 (level 
IV). Taking into account intraoperative bile leak and the 
incidence of PSR, LC is not recommended for suspected 
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prognostic factors include UICC stage, lymph node 
metastasis, depth of invasion, bile duct invasion, hepatic 
invasion, hepatoduodenal ligament invasion, perineural 
invasion, histological type, and curability
74,95,96  (level 
IV).
The UICC stage shows the degree of cancer exten-
sion and it is a matter of fact that more advanced cancer 
has a poorer prognosis. Of the TN factors, the most 
important prognostic factor in advanced gallbladder 
cancer is lymph node metastasis, which is also reported 
to be an independent prognostic factor on the basis of 
multivariate analysis
92,95,97  (level IV). In reports from 
Western countries, most of the long-term survivors with 
T3, T4 gallbladder cancer had N0 disease.
92  On the 
other hand, there is a report showing that, in Japan, 
the prognosis of N1 patients (metastasis limited to the 
lymph node within the hepatoduodenal ligament) was 
improved by lymph node dissection and that no signiﬁ  -
cant difference was found between the 5-year survivals 
of N0 patients (66%) and N1 patients (53%)
98 (level 
IV). There is a report which shows that, for N2 patients 
(metastasis to the lymph node around the pancreas 
head), the 5-year survival rate remains at 16%, which is 
poorer compared with that of N1.
98 Also, there is a study 
which reports that no difference was observed in the 5-
year survival rates between N1 and N2 disease and that 
N3 (paraaortic lymph node metastasis) disease had a 
poor prognosis
11 (level IV).
Another important prognostic factor, as well as lymph 
node metastasis, is thought to be hepatoduodenal liga-
ment invasion. In Japan, it has been reported that hepa-
toduodenal ligament invasion is an important prognostic 
factor
99 (level IV), while reports mentioning hepatoduo-
denal ligament invasion are rare in Western countries. 
The local extension of gallbladder cancer is a T factor, 
such as ﬁ  ndings of depth of mural invasion, bile duct 
invasion, and liver invasion, but hepatoduodenal liga-
ment invasion is a ﬁ  nding that shows not only bile duct 
invasion but also cancer cell inﬁ  ltration into the inter-
stitial tissues within the hepatoduodenal ligament. As a 
histological ﬁ  nding of gallbladder cancer, perineural 
invasion has also been reported to be a factor responsi-
ble for poor prognosis,
98  and this invasion is closely 
associated with bile duct invasion. It has also been made 
clear that perineural invasion is an independent factor 
responsible for poor prognosis
95,97 (level IV).
On the basis of univariate analysis concerning UICC 
stage I-IV gallbladder cancer, it was reported that the 
degree of histological differentiation of gallbladder 
cancer was also a signiﬁ  cant prognostic factor
74,95 (level 
IV). However, another study of this disease notes that, 
except for that in stage I, the degree of differentiation 
is not always an important prognostic factor.
92 Most T1 
cancers are papillary adenocarcinomas or well differen-
tiated tubular adenocarcinomas without lymph node 
Table 4.  UICC staging of gallbladder cancer
Stage grouping
  Stage 0 Tis N0 M0
  Stage IA T1 N0 M0
  Stage IB T2 N0 M0
  Stage IIA T3 N0 M0
  Stage IIB T1, 2, 3 N1 M0
  Stage III T4 Any N M0
  Stage IV Any T Any N M1
TNM Classiﬁ  cation summary
T1, gallbladder wall; T1a, lamina propria; T1b, muscle; T2, perimuscular 
connective tissue; T3, serosa, one organ and/or liver; T4, portal vein, 
hepatic artery, or two or more  extrahepatic organs; N1, regional 
lymph node metastasis
CQ 10 What are the prognostic factors after resec-
tion of gallbladder cancer?
Included in these factors are depth of mural invasion; 
lymph node metastasis; extramural extension,, 
especially into the hepatoduodenal ligament; 
perineural invasion; and the degree 
of curability.
The 5-year survival rate of patients after the resection 
of advanced gallbladder cancer is 33%–65% for Inter-
national Union Against Cancer (UICC) stage III and 
8%–25% for stage IV, and its prognosis is clearly poorer 
compared with that of stage I (79%–91%) and stage 
II (64%–85%)
82,92–94 (level IV). See Table 4 for UICC 
staging of gallbladder cancer.
There are many studies concerning prognostic factors 
after the resection of gallbladder cancer, and signiﬁ  cant 
cystic duct stump is negative
77,78 (level IV). However, 
in gallbladder cancer invading the subserosal layer, 
high rates of vascular and perineural invasion
79–81 and 
positive lymph node metastasis (40%–50%) are 
observed.
81–85
Although there is no RCT concerning additional 
resection, there are retrospective studies reporting that, 
in patients with gallbladder cancer invading the subse-
rosal layer or deeper, prognosis is signiﬁ  cantly better in 
the group for whom additional resection has been per-
formed compared with the group who received simple 
cholecystectomy alone
66,77,86,87  (level IV). Thus, it is 
thought that in gallbladder cancer invading the subse-
rosal layer or more, a curative second operation includ-
ing hepatectomy and lymphadenectomy, when necessary, 
should be considered
88–91 (level V). However, in patients 
with advanced extracystic extension, the successful 
resection rate in second operations and the 5-year sur-
vival rate after resection are low and prognosis is 
poor
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CQ 12  What prognostic factors are there after resec-
tion of ampullary carcinoma?
Included in these factors are lymph node metastasis, 
pancreas invasion, and perineural invasion.
Among biliary tract cancers, the prognosis of ampullary 
carcinoma is relatively good, but its prognosis is slightly 
poorer than that of digestive tract cancer. In patients 
without distant metastasis, curative resection is of the 
utmost importance, and such resection can be carried 
out for most ampullary carcinomas.
In biliary tract cancers, lymph node metastasis and 
perineural invasion are important modes of extension.
111 
There are many reports demonstrating that the pres-
ence or absence of lymph node metastasis has a large 
impact on prognosis in ampullary carcinoma
2,110,112–114 
(level IV). There is a report indicating that the fre-
quency of perineural invasion is lower than that in bile 
duct cancer, but that this invasion is also an important 
prognostic factor
115 (level IV).
Pancreatic invasion is also a signiﬁ  cant mode of exten-
sion, and the prognosis of patients with pancreatic inva-
sion is poorer than that of patients with no pancreatic 
CQ 11 For which type of ampullary carcinoma is 
limited operation recommended?
Pancreaticoduodenectomy (PD) is indicated for 
ampullary carcinoma in general, but limited 
operation is also indicated in patients with 
carcinoma in adenoma (recommendation C1).
Pancreaticoduodenectomy (PD) remains as a standard 
surgical procedure for ampullary carcinoma, and 
improved operative techniques and perioperative man-
agement have contributed to better results. It is reported, 
on the basis of pathological examination, that the rate 
of lymph node metastasis is low in ampullary cancers 
not extending beyond the sphincter of Oddi
102,103 (level 
IV). Under these circumstances, there have been many 
reports in recent years on a variety of limited operation 
as curative surgery for ampullary cancer. However, 
there are no reports of RCTs concerning limited opera-
tion and standard operation. Furthermore, resections 
with curative intent and palliative resections selected 
for patients in poor general conditions are intermingled 
in these reports, thus making an accurate assessment 
of treatment results difﬁ  cult. Knox and Kingston
104 
reported, in their case-series study (level IV), that the 
survival rate after local resection was slightly better 
than that after PD. Goldberg et al.
105 and Sharp et al.
106 
(level IV) reported that the results of local resection 
metastasis, and the prognosis is good, whereas in T3-4 
cancers, the prognosis is poor. The difference in progno-
sis between T1 and T3-4 cancers is possibly caused by 
the ﬁ  nding that even well-differentiated tubular adeno-
carcinomas in the latter are frequently associated with 
lymph node metastasis.
98
Also, similar to ﬁ  ndings in other malignant cancers, 
the degree of curability after surgical resection is a prog-
nostic factor
92 (level IV). Gallbladder cancer shows a 
variety of modes of spread to the surrounding organs, 
such as lymph node metastasis, liver invasion, hepato-
duodenal ligament invasion, duodenal invasion, and 
transverse colon invasion, so the selection of surgical 
procedures according to the modes of tumor spread and 
the achievement of R0 are considered to be of great 
signiﬁ  cance
14,15,99 (level IV). Furthermore, there are a 
few reports demonstrating that, even for advanced gall-
bladder cancer presumed to have poor prognosis due to 
lymph node metastasis (N2) or hepatoduodenal liga-
ment invasion, long-term survival may be achieved by 
R0 resection with the use of hepatic resection plus PD 
(extended lymph node dissection)
100,101 (level IV). Long-
term survival is not expected in patients who have had 
R1 or R2 resections.
were safe and as good as those of PD. On the other 
hand, there is a report demonstrating that a higher rate 
of recurrence was observed for limited surgery than 
was observed for PD. Also, Branum et al.
107 (level IV) 
reported that cancer recurred in six of eight patients 
with local resection.
Concerning indications for limited surgery, Klein et 
al.
108 (level IV) reported that local resection was indi-
cated for adenoma or T1N0 tumors, whereas Paramy-
thiotis et al.
109 (level IV) suggested that it was indicated 
for adenoma with high-grade dysplasia and villous, 
tubulovillous, or tubular adenomas less than 2 cm in size. 
Beger et al.
110 (level IV) reported that carcinoma was 
found in 26% of resected patients with a preoperative 
diagnosis of papillary adenoma, thus concluding that 
patients with pTis, pT1, N0, M0, G1, or G2 disease were 
indicated for limited surgery and that local lymph node 
dissection should be performed for these patients.
At present, making a diagnosis of cancer invasion to 
the sphincter of Oddi is difﬁ  cult, so no consensus has 
been reached on the usefulness of local resection in 
patients with a deﬁ  nite diagnosis of malignancy. To 
apply limited surgery for this disease, improved diag-
nostic precision and the results of RCTs will be neces-
sary, but at present, indications for limited surgery are 
adenoma or cancer in adenoma with a low possibility 
of invasion of the sphincter of Oddi. Also, endoscopic 
ampullectomy is being attempted for adenoma.S. Kondo et al.: Guidelines for the surgical treatment of biliary cancer  51
invasion
115  (level IV). Furthermore, there is a report 
indicating that the gross tumor appearance is also an 
important prognostic factor
113 (level IV), but this factor 
is closely correlated with lymph node metastasis.
In summary, detailed investigation of the extension 
of ampullary carcinoma makes possible the prediction 
of a high risk of recurrence, and strict follow-up and 
adjuvant therapy after resection should be considered 
in such high-risk patients.
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